Revenue Growth Acceleration
Revenue jumped from $12.7B in Q1 2025 to $19.8B in Q1 2026, a 55.5% YoY increase, reflecting strong commercial momentum across Lilly's key therapeutic franchises, particularly in diabetes and obesity treatments.
ELI LILLY & Co is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Eli Lilly delivered an exceptional Q1 2026, with revenue surging 55.5% YoY to $19.8B and net income soaring 168.1% to $7.4B, driven by continued explosive demand for its GLP-1 and diabetes/obesity portfolio.
Drawn from management commentary in the Q1 2026 10-Q:
Revenue jumped from $12.7B in Q1 2025 to $19.8B in Q1 2026, a 55.5% YoY increase, reflecting strong commercial momentum across Lilly's key therapeutic franchises, particularly in diabetes and obesity treatments.
Net income grew 168.1% YoY to $7.4B, with net margin expanding dramatically to 37.4% from approximately 21.7% in the prior year period, indicating significant operating leverage as revenue scales faster than costs.
Cost of revenue rose 60.8% YoY to $3.6B, slightly faster than revenue growth of 55.5%, suggesting some manufacturing scale-up costs, though gross profit still expanded substantially in absolute terms.
Revenue
$19.8B
++55.54% YoY
EPS (Basic)
$8.27
++169.38% YoY
Add LLY to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.